Clinical trial results:
A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients with Primary Immune Thrombocytopenia followed by an Open-Label Treatment Period

Summary

EudraCT number	2016-003038-26
Trial protocol	GB HU CZ BE DE AT ES
Global end of trial date	09 April 2019

Results information

Result version number	v1 (current)
This version publication date	03 May 2020
First version publication date	03 May 2020

Trial information

Trial identification

Sponsor protocol code	ARGX-113-1603

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03102593
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	argenx BVBA
Sponsor organisation address	Industriepark-Zwijnaarde 7, Zwijnaarde, Belgium, 9052
Public contact	Regulatory Manager, argenx BVBA, +32 93103400, regulatory@argenx.com
Scientific contact	Regulatory Manager, argenx BVBA, +32 93103400, regulatory@argenx.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 April 2019
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	09 April 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the safety and tolerability of ARGX-113.

Protection of trial subjects:

This study was conducted, and the informed consent was obtained according to the ethical principles stated in the Declaration of Helsinki (latest version), the applicable guidelines for Good Clinical Practice, or the applicable drug and data protection laws and regulations of the countries where the study was conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	30 March 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 2
Country: Number of subjects enrolled	Spain: 6
Country: Number of subjects enrolled	United Kingdom: 3
Country: Number of subjects enrolled	Belgium: 1
Country: Number of subjects enrolled	Czech Republic: 3
Country: Number of subjects enrolled	France: 1
Country: Number of subjects enrolled	Hungary: 14
Country: Number of subjects enrolled	Ukraine: 8
Worldwide total number of subjects	38
EEA total number of subjects	30

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	34
From 65 to 84 years	4
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

From 30 March 2017, 38 patients with Primary Immune Thrombocytopenia (ITP) were randomized in 19 study centers in Ukraine and Europe into a double-blind main study. Eligible patients continued into an optional open-label treatment period. The last patient last visit was 09 April 2019.

Pre-assignment

Screening details:

Patients were randomized into the main study in a 1:1:1 ratio to receive either ARGX-113 at 5 or 10 milligram/kilogram (mg/kg) body weight or placebo, in addition to Standard of Care (SoC). During screening, average platelet counts had to be <30×10^9/Liter (L) with no single reading >35×10^9/L, measured on 2 separate occasions at least 1 day apart.

Period 1

Period 1 title	Main Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	ARGX-113 5 mg/kg

Arm description:

The main study included a 2-week screening, a 3-week treatment period (visit 1 through visit 7), and an 8-week follow-up period (visit 8 through visit 16). Patients received ARGX-113 at a dose of 5 mg/kg in 4 intravenous (IV) infusions, administered 1 week apart, in addition to SoC.

Patients who completed the initial 8-week follow-up and did not receive any rescue treatment were given the option of an extended follow-up period, up to maximum 13 weeks after visit 16.

Arm type	Experimental
Investigational medicinal product name	ARGX-113
Investigational medicinal product code	
Other name	Efgartigimod
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

ARGX-113 was supplied as 20 mg/millilters (mL) sterile, colorless, and clear concentrate solution for IV administration, administered in total volume of 250 mL over a period of 2 hours.

Arm title	ARGX-113 10 mg/kg

Arm description:

The main study included a 2-week screening, a 3-week treatment period (visit 1 through visit 7), and an 8-week follow-up period (visit 8 through visit 16). Patients received ARGX-113 at a dose of 10 mg/kg in 4 IV infusions, administered 1 week apart, in addition to SoC.

Patients who completed the initial 8-week follow-up and did not receive any rescue treatment were given the option of an extended follow-up period, up to maximum 13 weeks after visit 16.

Arm type	Experimental
Investigational medicinal product name	ARGX-113
Investigational medicinal product code	
Other name	Efgartigimod
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

ARGX-113 was supplied as 20 mg/mL sterile, colorless, and clear concentrate solution for IV administration, administered in total volume of 250 mL over a period of 2 hours.

Arm title	Placebo

Arm description:

The main study included a 2-week screening, a 3-week treatment period (visit 1 through visit 7), and an 8-week follow-up period (visit 8 through visit 16). Patients received matching placebo in 4 IV infusions, administered 1 week apart, in addition to SoC.

Patients who completed the initial 8-week follow-up and did not receive any rescue treatment were given the option of an extended follow-up period, up to maximum 13 weeks after visit 16.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

A matching placebo was supplied as a sterile, colorless, and clear concentrate solution for IV administration, administered in total volume of 250 mL over a period of 2 hours.

Number of subjects in period 1	ARGX-113 5 mg/kg	ARGX-113 10 mg/kg	Placebo
Started	13	13	12
Entered Main Study Extended Follow-up	6 [1]	6 [2]	2 [3]
Completed	13	11	8
Not completed	0	2	4
Consent withdrawn by subject	-	1	1
Unspecified	-	1	-
Lack of efficacy	-	-	3

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Patients classed as completing the study had completed up to visit 16 (treatment period plus 8 weeks follow-up). The optional extended follow-up period began after completion of the main study.
[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Patients classed as completing the study had completed up to visit 16 (treatment period plus 8 weeks follow-up). The optional extended follow-up period began after completion of the main study.)
[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Patients classed as completing the study had completed up to visit 16 (treatment period plus 8 weeks follow-up). The optional extended follow-up period began after completion of the main study.

Baseline characteristics

Reporting groups	
Reporting group title	ARGX-113 5 mg/kg

Reporting group description:

The main study included a 2-week screening, a 3-week treatment period (visit 1 through visit 7), and an 8-week follow-up period (visit 8 through visit 16). Patients received ARGX-113 at a dose of 5 mg/kg in 4 intravenous (IV) infusions, administered 1 week apart, in addition to SoC.

Patients who completed the initial 8-week follow-up and did not receive any rescue treatment were given the option of an extended follow-up period, up to maximum 13 weeks after visit 16.

Reporting group title	ARGX-113 10 mg/kg

Reporting group description:

The main study included a 2-week screening, a 3-week treatment period (visit 1 through visit 7), and an 8-week follow-up period (visit 8 through visit 16). Patients received ARGX-113 at a dose of 10 mg/kg in 4 IV infusions, administered 1 week apart, in addition to SoC.

Patients who completed the initial 8-week follow-up and did not receive any rescue treatment were given the option of an extended follow-up period, up to maximum 13 weeks after visit 16.

Reporting group title	Placebo

Reporting group description:

The main study included a 2-week screening, a 3-week treatment period (visit 1 through visit 7), and an 8-week follow-up period (visit 8 through visit 16). Patients received matching placebo in 4 IV infusions, administered 1 week apart, in addition to SoC.

Patients who completed the initial 8-week follow-up and did not receive any rescue treatment were given the option of an extended follow-up period, up to maximum 13 weeks after visit 16.

Reporting group values	ARGX-113 5 mg/kg	ARGX-113 10 mg/kg	Placebo
Number of subjects	13	13	12
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years			
arithmetic mean	45.7	45.5	41.8
standard deviation	± 18.41	± 12.75	± 16.41
Gender categorical Units: Subjects			
Female	9	4	7
Male	4	9	5

Race Units: Subjects			
White	12	13	11
Not Reported	1	0	1
Platelet Count Level at Baseline Units: Subjects			
Baseline Platelet Count Level <15 x 10^9/L	7	7	6
Baseline Platelet Count Level >=15 x 10^9/L	6	6	6
Patients with Previous ITP Therapy			
Patients who had received at least 1 ITP therapy, either previously received or ongoing at Baseline.			
Units: Subjects			
Patients with previous ITP therapy	13	12	12
Patients with no previous ITP therapy	0	1	0
ITP Therapy Ongoing at Baseline			
Patients who had received at least 1 ITP therapy which was ongoing at Baseline.			
Units: Subjects			
ITP therapy ongoing at Baseline	11	8	8
ITP therapy not ongoing at Baseline	2	5	4
Body Weight Units: kg			
arithmetic mean	80.32	86.96	78.73
standard deviation	± 15.591	± 22.280	± 18.811
Duration of ITP Prior to Screening Units: years			
median	4.46	5.42	3.51
full range (min-max)	0.1 to 34.2	0.7 to 28.7	0.3 to 47.8
Number of Unique ITP Therapies			
Median number of unique ITP therapies, either previously received or ongoing at Baseline.			
Units: Unique ITP therapies			
median	2.00	1.00	2.00
full range (min-max)	1.0 to 8.0	0.0 to 10.0	1.0 to 7.0

Reporting group values	Total		
Number of subjects	38		
Age categorical Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	0		
From 65-84 years	0		
85 years and over	0		
Age continuous Units: years			
arithmetic mean			

standard deviation	-		

Gender categorical Units: Subjects			
Female	20		
Male	18		
Race Units: Subjects			
White	36		
Not Reported	2		
Platelet Count Level at Baseline Units: Subjects			
Baseline Platelet Count Level <15 x 10^9/L	20		
Baseline Platelet Count Level >=15 x 10^9/L	18		
Patients with Previous ITP Therapy			
Patients who had received at least 1 ITP therapy, either previously received or ongoing at Baseline.			
Units: Subjects			
Patients with previous ITP therapy	37		
Patients with no previous ITP therapy	1		
ITP Therapy Ongoing at Baseline			
Patients who had received at least 1 ITP therapy which was ongoing at Baseline.			
Units: Subjects			
ITP therapy ongoing at Baseline	27		
ITP therapy not ongoing at Baseline	11		
Body Weight Units: kg arithmetic mean standard deviation	- -		
Duration of ITP Prior to Screening Units: years median full range (min-max)	- -		
Number of Unique ITP Therapies			
Median number of unique ITP therapies, either previously received or ongoing at Baseline.			
Units: Unique ITP therapies median full range (min-max)	- -		

End points

End points reporting groups

Reporting group title	ARGX-113 5 mg/kg

Reporting group description:

The main study included a 2-week screening, a 3-week treatment period (visit 1 through visit 7), and an 8-week follow-up period (visit 8 through visit 16). Patients received ARGX-113 at a dose of 5 mg/kg in 4 intravenous (IV) infusions, administered 1 week apart, in addition to SoC.

Patients who completed the initial 8-week follow-up and did not receive any rescue treatment were given the option of an extended follow-up period, up to maximum 13 weeks after visit 16.

Reporting group title	ARGX-113 10 mg/kg

Reporting group description:

The main study included a 2-week screening, a 3-week treatment period (visit 1 through visit 7), and an 8-week follow-up period (visit 8 through visit 16). Patients received ARGX-113 at a dose of 10 mg/kg in 4 IV infusions, administered 1 week apart, in addition to SoC.

Patients who completed the initial 8-week follow-up and did not receive any rescue treatment were given the option of an extended follow-up period, up to maximum 13 weeks after visit 16.

Reporting group title	Placebo

Reporting group description:

The main study included a 2-week screening, a 3-week treatment period (visit 1 through visit 7), and an 8-week follow-up period (visit 8 through visit 16). Patients received matching placebo in 4 IV infusions, administered 1 week apart, in addition to SoC.

Patients who completed the initial 8-week follow-up and did not receive any rescue treatment were given the option of an extended follow-up period, up to maximum 13 weeks after visit 16.

Subject analysis set title	ARGX-113 5 mg/kg
Subject analysis set type	Safety analysis

Subject analysis set description:

Patients received 5 mg/kg ARGX-113 in 4 IV infusions 1 week apart (up to visit 16) and SoC.

Patients who completed the initial 8-week follow-up period (visit 16) and did not receive any rescue treatment were given the option to participate in an extended follow-up period, up to a maximum 13 weeks after visit 16.

Safety analysis set included all patients who had received any portion of study drug.

Subject analysis set title	ARGX-113 10 mg/kg
Subject analysis set type	Safety analysis

Subject analysis set description:

Patients received 10 mg/kg ARGX-113 in 4 IV infusions 1 week apart (up to visit 16) and SoC.

Patients who completed the initial 8-week follow-up period (visit 16) and did not receive any rescue treatment were given the option to participate in an extended follow-up period, up to a maximum 13 weeks after visit 16.

Safety analysis set included all patients who had received any portion of study drug.

Subject analysis set title	Placebo
Subject analysis set type	Safety analysis

Subject analysis set description:

Patients received placebo in 4 IV infusions 1 week apart (up to visit 16) and SoC.

Patients who completed the initial 8-week follow-up period (visit 16) and did not receive any rescue treatment were given the option to participate in an extended follow-up period, up to a maximum 13 weeks after visit 16

Safety analysis set included all patients who had received any portion of study drug.

Subject analysis set title	ARGX-113 5 mg/kg
Subject analysis set type	Safety analysis

Subject analysis set description:

Patients received 5 mg/kg ARGX-113 in 4 IV infusions 1 week apart (up to visit 16) and SoC.
Patients who completed the initial 8-week follow-up period (visit 16) and did not receive any rescue treatment were given the option to participate in an extended follow-up period, up to a maximum 13 weeks after visit 16.
Safety analysis set included all patients who had received any portion of study drug.

Subject analysis set title	ARGX-113 10 mg/kg
Subject analysis set type	Safety analysis

Subject analysis set description:

Patients received 10 mg/kg ARGX-113 in 4 IV infusions 1 week apart (up to visit 16) and SoC.
Patients who completed the initial 8-week follow-up period (visit 16) and did not receive any rescue treatment were given the option to participate in an extended follow-up period, up to a maximum 13 weeks after visit 16.
Safety analysis set included all patients who had received any portion of study drug.

Subject analysis set title	Placebo
Subject analysis set type	Safety analysis

Subject analysis set description:

Patients received placebo in 4 IV infusions 1 week apart (up to visit 16) and SoC.
Patients who completed the initial 8-week follow-up period (visit 16) and did not receive any rescue treatment were given the option to participate in an extended follow-up period, up to a maximum 13 weeks after visit 16.
Safety analysis set included all patients who had received any portion of study drug.

Subject analysis set title	ARGX-113 5 mg/kg
Subject analysis set type	Full analysis

Subject analysis set description:

Patients received 5 mg/kg ARGX-113 in 4 IV infusions 1 week apart (up to visit 16) and SoC.
Patients who completed the initial 8-week follow-up period (visit 16) and did not receive any rescue treatment were given the option to participate in an extended follow-up period, up to a maximum 13 weeks after visit 16.
Full analysis set included all randomized patients with at least 1 post-Baseline primary efficacy observation (platelet count results)

Subject analysis set title	ARGX-113 10 mg/kg
Subject analysis set type	Full analysis

Subject analysis set description:

Patients received 10 mg/kg ARGX-113 in 4 IV infusions 1 week apart (up to visit 16) and SoC.
Patients who completed the initial 8-week follow-up period (visit 16) and did not receive any rescue treatment were given the option to participate in an extended follow-up period, up to a maximum 13 weeks after visit 16.
Full analysis set included all randomized patients with at least 1 post-Baseline primary efficacy observation (platelet count results).

Subject analysis set title	Placebo
Subject analysis set type	Full analysis

Subject analysis set description:

Patients received placebo in 4 IV infusions 1 week apart (up to visit 16) and SoC.
Patients who completed the initial 8-week follow-up period (visit 16) and did not receive any rescue treatment were given the option to participate in an extended follow-up period, up to a maximum 13 weeks after visit 16.
Full analysis set included all randomized patients with at least 1 post-Baseline primary efficacy observation (platelet count results).

Subject analysis set title	ARGX-113 5 mg/kg
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Patients received 5 mg/kg ARGX-113 in 4 IV infusions 1 week apart (up to visit 16) and SoC.
Patients who completed the initial 8-week follow-up period (visit 16) and did not receive any rescue treatment were given the option to participate in an extended follow-up period, up to a maximum 13 weeks after visit 16.

Subject analysis set title	ARGX-113 10 mg/kg
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Patients received 10 mg/kg ARGX-113 in 4 IV infusions 1 week apart (up to visit 16) and SoC.
Patients who completed the initial 8-week follow-up period (visit 16) and did not receive any rescue treatment were given the option to participate in an extended follow-up period, up to a maximum 13 weeks after visit 16.

Subject analysis set title	Pooled ARGX-113
Subject analysis set type	Full analysis

Subject analysis set description:

Patients received either 5 or 10 mg/kg ARGX-113 in 4 IV infusions 1 week apart (up to visit 16) and SoC.

Patients who completed the initial 8-week follow-up period (visit 16) and did not receive any rescue treatment were given the option to participate in an extended follow-up period, up to a maximum 13 weeks after visit 16.

Subject analysis set title	Placebo
Subject analysis set type	Full analysis

Subject analysis set description:

Patients received placebo in 4 IV infusions 1 week apart (up to visit 16) and SoC.
Patients who completed the initial 8-week follow-up period (visit 16) and did not receive any rescue treatment were given the option to participate in an extended follow-up period, up to a maximum 13 weeks after visit 16.

Primary: Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs)

End point title	Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs)[1]

End point description:

TEAEs were defined as undesirable events not present prior to medical treatment, or already present events that worsened either in intensity or frequency following the treatment. A SAE was any untoward medical occurrence that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability or incapacity; was a congenital abnormality or birth defect; or other medically significant events. All TEAEs observed were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. Any patients experiencing a TEAE at Grade 3 or above are reported. Grade 3 = severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.

End point type	Primary

End point timeframe:

Main study: visit 1 to end of extended follow-up visit

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: As the primary endpoints were all safety analyses, no comparative statistics were planned.

End point values	ARGX-113 5 mg/kg	ARGX-113 10 mg/kg	Placebo	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	13	13	12	
Units: patients				
At least 1 TEAE	9	11	7	
At least 1 treatment-related TEAE	0	1	2	
At least 1 SAE	0	1	0	
At least 1 treatment-related SAE	0	0	0	
Withdrawn from treatment with at least SAE	0	1	0	
Discontinued due to at least 1 TEAE	0	1	0	

CTCAE severity Grade ≥3	0	1	0	
Number of Deaths	0	0	0	

Statistical analyses

No statistical analyses for this end point

Primary: Mean Change From Baseline in Vital Signs (Body Temperature)

End point title	Mean Change From Baseline in Vital Signs (Body

End point description:

The mean change from Baseline in body temperature at end of treatment (visit 7) and at end of study (visit 16) is summarized for the main study. Baseline was defined as the last non-missing measurement (including unscheduled assessments) taken prior to the first dose of study drug in the main study. Only patients with data available for analysis at each visit are presented.

End point type	Primary

End point timeframe:

Main study: Baseline, end of treatment (visit 7), end of study (visit 16)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: As the primary endpoints were all safety analyses, no comparative statistics were planned.

End point values	ARGX-113 5 mg/kg	ARGX-113 10 mg/kg	Placebo	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	13	12[3]	11[4]	
Units: degrees centigrade				
arithmetic mean (standard deviation)				
End of Treatment	0.22 (± 0.347)	0.16 (± 0.427)	-0.01 (± 0.277)	
End of Study	0.02 (± 0.316)	0.02 (± 0.447)	-0.04 (± 0.407)	

Notes:

[3] - End of Study: n=11

[4] - End of Study: n=8

Statistical analyses

No statistical analyses for this end point

Primary: Change in Physical Examination Abnormalities

End point title	Change in Physical Examination Abnormalities[5]

End point description:

Physical examination of different body systems or parameters were measured and categorized as either: Normal; Abnormal, same as previous assessment; Abnormal, new or worsened or Not Done. The number of patients recorded in the 'Abnormal, new or worsened' category at end of treatment (visit 7) and at end of study (visit 16) are summarized to represent a change across the study. Only patients with data available for analysis at each visit are presented.

End point type	Primary

End point timeframe:

Main study: end of treatment (visit 7), end of study (visit 16)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: As the primary endpoints were all safety analyses, no comparative statistics were planned.

End point values	ARGX-113 5 mg/kg	ARGX-113 10 mg/kg	Placebo	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	13	13[6]	12[7]	
Units: patients				
Abdomen: End of Treatment	0	0	0	
Abdomen: End of Study	0	0	0	
Breast: End of Treatment	0	0	0	
Breast: End of Study	0	0	0	
Cardiovascular: End of Treatment	0	0	0	
Cardiovascular: End of Study	0	0	0	
General Appearance: End of Treatment	0	0	0	
General Appearance: End of Study	0	0	0	
Genital/Rectal: End of Treatment	1	0	0	
Genital/Rectal: End of Study	0	0	0	
Head and Neck: End of Treatment	0	1	0	
Head and Neck: End of Study	0	0	0	
Lymph Nodes: End of Treatment	0	0	0	
Lymph Nodes: End of Study	0	0	0	
Musculoskeletal/Extremities: End of Treatment	1	0	0	
Musculoskeletal/ Extremities: End of Study	0	0	0	
Neurological: End of Treatment	0	0	0	
Neurological: End of Study	0	0	0	
Respiratory: End of Treatment	0	0	0	
Respiratory: End of Study	0	0	0	
Skin: End of Treatment	2	1	0	
Skin: End of Study	2	0	0	
Thyroid: End of Treatment	0	0	0	
Thyroid: End of Study	0	0	0	

Notes:

[6] - General Appearance: End of Study: n=11

[7] - General Appearance: End of Study: n = 7

Statistical analyses

No statistical analyses for this end point

Primary: Mean Change From Baseline in Electrocardiogram (ECG) Parameters

End point title	Mean Change From Baseline in Electrocardiogram (ECG) Parameters[8]

End point description:

ECG parameters were measured and the QT correction factor was based on both the Bazett and Fridericia formulae (QTcF). The mean change from Baseline values in QT interval and QTcF interval to the last observation on treatment up to visit 7 is summarized with the mean of ECG readings for each visit and parameter in the main study used for analysis. Baseline was defined as the last non-missing measurement (including unscheduled assessments) taken prior to the first dose of study drug in the main study. Only patients with data available for analysis at each visit are presented.

End point type	Primary

End point timeframe:

Main study: from Baseline to end of treatment (visit 7)

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: As the primary endpoints were all safety analyses, no comparative statistics were planned.

End point values	ARGX-113 5 mg/kg	ARGX-113 10 mg/kg	Placebo	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	13	11	11	
Units: milliseconds (msec)				
arithmetic mean (standard deviation)				
QT Interval	2.27 (± 34.229)	2.32 (± 34.113)	5.32 (± 33.685)	
QTcF Interval	2.31 (± 37.641)	0.50 (± 18.087)	-1.00 (± 22.762)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Change From Baseline in Laboratory Parameters (Platelets)

End point title	Mean Change From Baseline in Laboratory Parameters (Platelets)

End point description:

Blood platelet count was measured at baseline and at every study visit. Baseline was defined as the last non-missing measurement (including unscheduled assessments) taken prior to the first dose of study drug in the main study. Any changes in laboratory values that were classed as clinically significant, required therapy or led to treatment discontinuation are captured in the adverse events (AE) section. The mean change from baseline in platelets at end of treatment (visit 7) and at end of study (visit 16) are summarized for the main study. Only patients with data available for analysis at each visit are presented.

End point type	Secondary

End point timeframe:

Main study: Baseline, end of treatment (visit 7), end of study (visit 16)

End point values	ARGX-113 5 mg/kg	ARGX-113 10 mg/kg	Placebo	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	12	11[9]	10[10]	
Units: 10^9/L				
arithmetic mean (standard deviation)				
End of Treatment	24.8 (± 60.43)	21.2 (± 33.56)	10.6 (± 29.40)	
End of Study	60.3 (± 126.67)	57.5 (± 108.62)	9.4 (± 13.33)	

Notes:

[9] - End of Treatment: n = 10

[10] - End of Study: n = 7

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Patients With a Platelet Count Response

End point title	Percentage of Patients With a Platelet Count Response

End point description:

The percentage of patients reaching any of the following platelet count thresholds at any time during the main study were reported:

• Initial response: platelet count ≥30 × 10^9/L, and/or at least doubling of the Baseline count and absence of bleeding at any time during the study.
• Confirmed complete response: platelet count ≥100 × 10^9/L, confirmed on at least 2 separate consecutive occasions ≥7 days apart, and the absence of bleeding.
• Confirmed response: platelet count ≥30 × 10^9/L and <100 × 10^9/L, and a greater than 2-fold increase in platelet count from Baseline, confirmed on at least 2 separate consecutive occasions ≥7 days apart, and the absence of bleeding.
• No response: platelet count <30 × 10^9/L or less than doubling of the Baseline count or bleeding.
• Platelet count ≥50 × 10^9/L: platelet count increased to at least 50 × 10^9/L at any time during the study.
Only patients with data available for analysis at each visit are presented.

End point type	Secondary

End point timeframe:

Main study: from Baseline to end of study (visit 16)

End point values	ARGX-113 5 mg/kg	ARGX-113 10 mg/kg	Placebo	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	13	13	12	
Units: percentage of patients				
number (confidence interval 95%)				
Initial Response	23.1 (5.04 to 53.81)	38.5 (13.86 to 68.42)	33.3 (9.92 to 65.11)	
Confirmed Complete Response	15.4 (1.92 to 45.45)	23.1 (5.04 to 53.81)	0.0 (0.00 to 22.09)	
Confirmed Response	23.1 (5.04 to 53.81)	15.4 (1.92 to 45.45)	16.7 (2.09 to 48.41)	
No Response	46.2 (19.22 to 74.87)	53.8 (25.13 to 80.78)	66.7 (34.89 to 90.08)	
Platelet ≥50 × 10^9/L	53.8 (25.13 to 80.78)	53.8 (25.13 to 80.78)	50.0 (21.09 to 78.91)	

Statistical analyses

No statistical analyses for this end point

Secondary: Pharmacokinetic (PK) Parameters - Serum Concentrations of ARGX-113

End point title	Pharmacokinetic (PK) Parameters - Serum Concentrations of ARGX-113

End point description:

The appropriate PK parameters were calculated after single (visit 1) and multiple administrations (visits 3, 5, and 7) of ARGX-113. The mean maximum observed serum concentration (Cmax) and serum concentration at the end of the dosing interval (Ctrough) is summarized for all visits in the main study.

All patients who had at least 1 serum concentration data after the start of ARGX-113 treatment without major protocol violations/deviations thought to impact PK are included in the PK analysis set. Only patients with data available for analysis are presented.

End point type	Secondary

End point timeframe:

Main study: visit 1 (day 1), visit 3 (day 8), visit 5 (day 15) and end of treatment (visit 7/day 22)

End point values	ARGX-113 5 mg/kg	ARGX-113 10 mg/kg		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13[11]	13[12]		
Units: nanograms (ng)/mL				
geometric mean (geometric coefficient of variation)				
Cmax: Visit 1	120500 (± 35.2)	190800 (± 21.2)		
Cmax: Visit 3	114000 (± 40.2)	173700 (± 14.7)		
Cmax: Visit 5	92100 (± 29.0)	152200 (± 19.0)		
Cmax: Visit 7	116600 (± 31.0)	190000 (± 23.1)		
Ctrough: Visit 1	4870 (± 40.4)	7906 (± 25.8)		
Ctrough: Visit 3	5518 (± 37.1)	8748 (± 8.7)		
Ctrough: Visit 5	6587 (± 39.2)	12060 (± 41.4)		
Ctrough: Visit 7	5498 (± 62.0)	9851 (± 48.0)		

Notes:

[11] - Cmax: Visit 1: N = 12

[12] - Cmax visits 1,3,5, Ctrough visit 3: n =12
Cmax visit 7, Ctrough visit 5, 7: n= 11

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Patients With an Anti-drug Antibodies (ADA) Response

End point title	Number of Patients With an Anti-drug Antibodies (ADA) Response

End point description:

Blood samples to assess ADA were collected pre-dose on all study drug infusion days. The number of patients with a positive and negative ADA response at Baseline, end of treatment (visit 7), end of study (visit 16) in the main study are summarized. Baseline was defined as the last non-missing measurement (including unscheduled assessments) taken prior to the first dose of study drug in the main study. All patients who had received at least 1 dose of study drug without major protocol violations/deviations thought to impact PD were included in the PD analysis set. Only patients with data available for analysis are presented.

End point type	Secondary

End point timeframe:

Main study: Baseline, end of treatment (visit 7), end of study (visit 16)

End point values	ARGX-113 5 mg/kg	ARGX-113 10 mg/kg	Placebo	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	13	13[13]	12[14]	
Units: patients				
Positive: Baseline	1	3	2	
Negative: Baseline	12	10	10	
Positive: End of Treatment	0	0	1	
Negative: End of Treatment	13	11	10	
Positive: End of Study	3	4	2	
Negative: End of Study	10	9	10	

Notes:

[13] - End of treatment: n = 11

[14] - End of Treatment: n = 11

Statistical analyses

No statistical analyses for this end point

Post-hoc: Percentage of Patients With Clinically Meaningful Platelet Count Response

End point title	Percentage of Patients With Clinically Meaningful Platelet Count Response

End point description:

A platelet count response of ≥50 x 10^9/L during two or more visits was classed as clinically meaningful. The percentage of patients with improved platelet count ≥50 x 10^9/L during two or more visits was recorded as a post hoc analysis.

End point type	Post-hoc

End point timeframe:

Main study: from Baseline to end of study (visit 16)

End point values	ARGX-113 5 mg/kg	ARGX-113 10 mg/kg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	13	13	12	
Units: percentage of patients				
number (confidence interval 95%)	46.2 (19.22 to 74.87)	46.2 (19.22 to 74.87)	25.0 (5.49 to 57.19)	

Statistical analyses

Statistical analysis title	Pooled ARGX-113 Treatment Groups Vs Placebo

Statistical analysis description:

Comparison of proportion between pooled ARGX-113 treatment groups and Placebo group based on exact logistic regression model adjusted for the platelet count category at Baseline.

Comparison groups	ARGX-113 5 mg/kg v ARGX-113 10 mg/kg v Placebo

Number of subjects included in analysis	38
Analysis specification	Post-hoc
Analysis type	other
P-value	= 0.3721
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	2.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.48
upper limit	17.51

Post-hoc: Cumulative Duration of Clinically Meaningful Platelet Count Response

End point title	Cumulative Duration of Clinically Meaningful Platelet Count Response

End point description:

A platelet count response of ≥50 x 10^9/L during two or more visits was classed as clinically meaningful. The mean cumulative duration of platelet count response in days was recorded for pooled ARGX-113 treatment groups and Placebo group and analysed based on a conservative approach where adjacent visits were considered for calculation of duration. If visits were not adjacent, only one day was considered as duration. This approach corresponds to treating missing platelet count levels as <50 x 10^9/L.

End point type	Post-hoc

End point timeframe:

Main study: from Baseline to end of study (visit 16)

End point values	Pooled ARGX-113	Placebo		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	26	12		
Units: days				
arithmetic mean (standard deviation)	24.6 (± 20.64)	7.7 (± 3.21)		

Statistical analyses

No statistical analyses for this end point

Post-hoc: Percentage of Patients With Cumulative Duration of Clinically Meaningful Platelet Count Response Greater Than 10 Days

End point title	Percentage of Patients With Cumulative Duration of Clinically Meaningful Platelet Count Response Greater Than 10 Days

End point description:

A platelet count response of ≥50 x 10^9/L during two or more visits was classed as clinically meaningful. Patients with a clinically meaningful platelet count response for at least 10 cumulative days was recorded for pooled ARGX-113 treatment groups and Placebo group and analysed based on a conservative approach where adjacent visits were considered for calculation of duration. If visits were

not adjacent, only one day was considered as duration. This approach corresponds to treating missing platelet count levels as <50 x 10^9/L.

End point type	Post-hoc

End point timeframe:

Main study: from Baseline to end of study (visit 16)

End point values	Pooled ARGX-113	Placebo		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	26	12		
Units: Percentage of patients				
number (not applicable)	38.46	0.00		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Main study: visit 1 to end of extended follow up visit (maximum of 176 days).

Adverse event reporting additional description:

TEAEs were monitored continuously from visit 1 until last study-related activity. In case of early discontinuation, any TEAEs/SAEs were assessed for 30 days following the patient's last visit or until satisfactory resolution or stabilization.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	19.1

Reporting groups

Reporting group title	ARGX-113 5 mg/kg

Reporting group description:

Patients received 5 mg/kg ARGX-113 in 4 IV infusions 1 week apart (up to visit 16) and SoC.
Patients who completed the initial 8-week follow-up period (visit 16) and did not receive any rescue treatment were given the option to participate in an extended follow-up period, up to a maximum 13 weeks after visit 16.

Reporting group title	ARGX-113 10 mg/kg

Reporting group description:

Patients received 10 mg/kg ARGX-113 in 4 IV infusions 1 week apart (up to visit 16) and SoC.
Patients who completed the initial 8-week follow-up period (visit 16) and did not receive any rescue treatment were given the option to participate in an extended follow-up period, up to a maximum 13 weeks after visit 16.

Reporting group title	Placebo

Reporting group description:

Patients received placebo in 4 IV infusions 1 week apart (up to visit 16) and SoC.
Patients who completed the initial 8-week follow-up period (visit 16) and did not receive any rescue treatment were given the option to participate in an extended follow-up period, up to a maximum 13 weeks after visit 16.

Serious adverse events	ARGX-113 5 mg/kg	ARGX-113 10 mg/kg	Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 12 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	ARGX-113 5 mg/kg	ARGX-113 10 mg/kg	Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	9 / 13 (69.23%)	11 / 13 (84.62%)	7 / 12 (58.33%)
Vascular disorders			
Haematoma			
subjects affected / exposed	3 / 13 (23.08%)	2 / 13 (15.38%)	0 / 12 (0.00%)
occurrences (all)	6	4	0
Hypertension			
subjects affected / exposed	0 / 13 (0.00%)	2 / 13 (15.38%)	1 / 12 (8.33%)
occurrences (all)	0	2	1
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Oedema periphera			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 12 (0.00%)
occurrences (all)	2	0	0
Pyrexia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Reproductive system and breast disorders			
Amenorrhoea			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	2
Menorrhagia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Metrorrhagia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Vaginal discharge			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			

Catarrh			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Dyspnoea			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Productive cough			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	1 / 12 (8.33%)
occurrences (all)	1	0	1
Psychiatric disorders			
Depressed mood			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Investigations			
Body temperature increased			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	0	2	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	1 / 13 (7.69%)	1 / 13 (7.69%)	1 / 12 (8.33%)
occurrences (all)	1	1	1
Scratch			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Subcutaneous haematoma			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Sinus bradycardia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	2 / 12 (16.67%)
occurrences (all)	1	0	2
Blood and lymphatic system disorders			

Anaemia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Iron deficiency anaemia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Ear and labyrinth disorders			
Ear congestion			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Angina bullosa haemorrhagica			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Constipation			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Dyspepsia			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Mouth haemorrhage			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Nausea			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Oral mucosal blistering			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Toothache			

subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Vomiting			
subjects affected / exposed	0 / 13 (0.00%)	2 / 13 (15.38%)	0 / 12 (0.00%)
occurrences (all)	0	2	0
Hepatobiliary disorders			
Hepatomegaly			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Ecchymosis			
subjects affected / exposed	1 / 13 (7.69%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	7	1	0
Petechiae			
subjects affected / exposed	2 / 13 (15.38%)	2 / 13 (15.38%)	1 / 12 (8.33%)
occurrences (all)	2	2	1
Pruritus			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	0	3	0
Purpura			
subjects affected / exposed	2 / 13 (15.38%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	2	1	0
Rash			
subjects affected / exposed	1 / 13 (7.69%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	1	1	0
Renal and urinary disorders			
Glycosuria			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Endocrine disorders			
Cushingoid			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue			

disorders			
Back pain			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Fibromyalgia			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Joint swelling			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Muscle oedema			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 12 (0.00%)
occurrences (all)	2	0	0
Pubic pain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	2
Tendonitis			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Cystitis			
subjects affected / exposed	1 / 13 (7.69%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	1	2	0
Oral herpes			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Tonsillitis			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Metabolism and nutrition disorders			

Decreased appetite			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Hypokalaemia			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
13 June 2017	The protocol was updated as follows: • to integrate the new toxicological data available on ARGX-113. • to include "wait and see" SoC treatment approach if it was according to local practice, and there was at least 1 prior line of therapy. • to include clarification on eligibility criteria. • to specify that during the follow-up period SoC of the patients were tapered by level of 25% at the discretion of the investigator when deemed medically indicated and only in patients who achieved CR (CR = platelet count >100 × 10^9/L confirmed on at least 2 separate occasions).
07 November 2017	The protocol was updated as follows: • the title of study was modified to include open-label treatment period. • the objectives, study design, study duration, inclusion and exclusion criteria, end points, and statistical sections were revised to reflect the inclusion of extended follow-up period and open-label treatment period. • for all randomized patients, platelet counts from the local laboratory was collected retrospectively/prospectively for all time points, from the patient's medical file after patient re-consent.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported